MARKET

PRLD

PRLD

Prelude Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.90
-0.37
-2.59%
After Hours: 13.90 0 0.00% 18:03 12/03 EST
OPEN
14.30
PREV CLOSE
14.27
HIGH
14.45
LOW
13.70
VOLUME
325.23K
TURNOVER
--
52 WEEK HIGH
95.38
52 WEEK LOW
13.03
MARKET CAP
656.29M
P/E (TTM)
-6.2151
1D
5D
1M
3M
1Y
5Y
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today...
Globe Newswire · 11/23 12:00
Notable Prelude Therapeutics Insider Trades $820K In Company Stock
Deborah Morosini, Insider at Prelude Therapeutics (NASDAQ:PRLD), made a large buy and sell of company shares on November 16, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Deborah ...
Benzinga · 11/19 16:51
Barclays Maintains Overweight on Prelude Therapeutics, Lowers Price Target to $20
Barclays analyst Peter Lawson maintains Prelude Therapeutics (NASDAQ:PRLD) with a Overweight and lowers the price target from $33 to $20.
Benzinga · 11/17 13:29
BRIEF-Prelude Therapeutics Inc Files For Mixed Shelf Of Up To $400 Million – SEC Filing
reuters.com · 11/12 21:09
BRIEF-Prelude Therapeutics Q3 Loss Per Share $0.66
reuters.com · 11/12 14:23
BRIEF-Prelude Therapeutics Announced Q3 Results
reuters.com · 11/12 14:19
Prelude Therapeutics EPS misses by $0.02
Prelude Therapeutics (NASDAQ:PRLD): Q3 GAAP EPS of -$0.66 misses by $0.02. Cash, cash equivalents, and marketable securities of $320.9M. Press Release
Seekingalpha · 11/12 13:35
Prelude Therapeutics Q3 EPS $(0.66) Up From $(5.25) YoY
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.66) per share. This is a 87.43 percent increase over losses of $(5.25) per share from the same period last year.
Benzinga · 11/12 13:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRLD. Analyze the recent business situations of Prelude Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRLD stock price target is 42.25 with a high estimate of 62.00 and a low estimate of 20.00.
High62.00
Average42.25
Low20.00
Current 13.90
EPS
Actual
Estimate
-0.54-0.41-0.27-0.14
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 62
Institutional Holdings: 42.07M
% Owned: 89.11%
Shares Outstanding: 47.22M
TypeInstitutionsShares
Increased
25
7.32M
New
9
65.72K
Decreased
12
350.35K
Sold Out
5
46.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.46%
Pharmaceuticals & Medical Research
-0.60%
Key Executives
Non-Executive Chairman/Independent Director
Paul Friedman
Chief Executive Officer/Founder/Director
Krishna Vaddi
Chief Financial Officer
Laurent Chardonnet
Executive Vice President
Andrew Combs
Executive Vice President
Deborah Morosini
Chief Scientific Officer
Peggy Scherle
Other
David Mauro
Director
Martin Babler
Independent Director
Julian Baker
Independent Director
David Bonita
Independent Director
Mardi Dier
Independent Director
Victor Sandor
No Data
About PRLD
Prelude Therapeutics Inc. is a clinical-stage precision oncology company. The Company is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The Company is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.

Webull offers kinds of Prelude Therapeutics Inc stock information, including NASDAQ:PRLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRLD stock methods without spending real money on the virtual paper trading platform.